heparitin-sulfate has been researched along with Liver-Failure--Acute* in 1 studies
1 other study(ies) available for heparitin-sulfate and Liver-Failure--Acute
Article | Year |
---|---|
Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure.
Acetaminophen/paracetamol (APAP) overdose is the leading cause of drug-induced acute liver failure (ALF) in the United States and Europe. The progression of the disease is attributed to sterile inflammation induced by the release of high mobility group box 1 (HMGB1) and the interaction with receptor for advanced glycation end products (RAGE). A specific, effective, and safe approach to neutralize the proinflammatory activity of HMGB1 is highly desirable. Here, we found that a heparan sulfate (HS) octadecasaccharide (18-mer-HP or hepatoprotective 18-mer) displays potent hepatoprotection by targeting the HMGB1/RAGE axis. Endogenous HS proteoglycan, syndecan-1, is shed in response to APAP overdose in mice and humans. Furthermore, purified syndecan-1, but not syndecan-1 core protein, binds to HMGB1, suggesting that HMGB1 binds to HS polysaccharide side chains of syndecan-1. Last, we compared the protection effect between 18-mer-HP and Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Europe; Heparitin Sulfate; Humans; Liver; Liver Failure, Acute; Mice; Mice, Inbred C57BL | 2020 |